The Lynx Group
Cholangiocarcinoma News

Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy

Web Exclusives — May 28, 2020

In patients with locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin, although mFOLFOX has been proven to be superior to active symptom control in the ABC-06 trial.1 Irinotecan is an active drug in other gastrointestinal cancers. This phase 2 study evaluated whether mFOLFIRI was superior to mFOLFOX in second-line treatment of patients with BTC.2

Patients diagnosed with BTC with disease progression after prior gemcitabine/cisplatin were randomized (1:1) to either mFOLFOX or mFOLFIRI. Randomization was stratified by tumor location (intrahepatic vs extrahepatic vs gallbladder vs ampulla of vater) and ECOG performance status (0, 1 vs 2). The primary end point was the overall survival (OS) rate at 6 months.

A total of 120 patients were enrolled in this study and 114 patients were treated (mFOLFOX: 56, mFOLFIRI: 58). The median age was 63 years. Most patients had ECOG 0/1 (89.5%). Tumor location was intrahepatic in 47 patients (41.2%), extrahepatic in 27 (23.7%), gallbladder in 35 (30.7%), and ampulla of vater in 5 (4.4%).

At the median follow-up duration of 25.8 months, the 6-month OS rate was 54.2% and 43.6% in the mFOLFOX and mFOLFIRI groups, respectively. Of 101 evaluable patients (mFOLFOX: 51, mFOFIRI: 50), the objective response rate and disease control rate were 5.9% and 66.7% with mFOLFOX and 4.0% and 64.4% with mFOLFIRI, respectively. Median progression-free survival was 2.8 months with mFOLFOX and 2.1 months with mFOLFIRI (P = .887). Median OS was 6.3 months with mFOLFOX and 5.7 months with mFOLFIRI (P = .472). The most common grade 3/4 adverse events were neutropenia (25.0%) and AST/ALT elevation (16.1%) in the mFOLFOX group and neutropenia (25.9%) and anemia (17.2%) in the mFOLFIRI group. Peripheral neuropathy (37.5%) and thrombocytopenia (37.5%) occurred more frequently in the mFOLFOX group, and vomiting (19.0%) and cholangitis (10.3%) occurred more frequently with mFOLFIRI. No chemotherapy-related deaths were reported.

The authors concluded that the mFOLFIRI regimen was tolerable but not superior to mFOLFOX as second-line therapy for BTC. ClinicalTrials.gov number NCT03464968.

References

  1. Lamarca A, et al. J Clin Oncol. 2019;37(15 suppl): Abstract 4003.
  2. Kim JW, et al. ASCO 2020. Abstract 4603.

Related Items

Zanidatamab Addresses an Unmet Need in Patients with HER2-Amplified Biliary Tract Cancer
December 2020, Vol 1, No 3
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the HER2 receptor) HER2-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the HER2 receptor.
Telotristat Ethyl and First-Line Chemotherapy Combination Investigated for Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
The metabolism of serotonin is dysregulated in cholangiocarcinoma (CCA) cell lines compared with normal cholangiocytes and in tissue and bile from patients with CCA.1 Telotristat ethyl (Xermelo) is a tryptophan hydroxylase inhibitor that is indicated for the treatment of patients with carcinoid syndrome–related diarrhea not well-controlled by somatostatin analog. Telotristat ethyl is currently being investigated for the treatment of patients with biliary tract cancer, including CCA tumors that express serotonin.
The Khorana Score Not Predictive of Thrombotic Events in Patients with Biliary Tract Cancer
December 2020, Vol 1, No 3
Cancer-related venous thromboembolism (VTE) is a significant cause of morbidity and mortality. There is a paucity of studies characterizing VTE in patients with biliary tract cancer; however, a few retrospective analyses suggest an incidence of VTE of up to 23%.
Benefits of Lenvatinib plus Pembrolizumab in Solid Tumors, Including Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
First results of the multicohort phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab combination immunotherapy has promising antitumor activity in patients with biliary tract cancer.
NTRK Gene Fusions in Biliary Tract Cancers
2020 Year in Review: Cholangiocarcinoma
Molecular analyses of biliary tract cancers indicate that neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare, suggesting that it is not a major driver of BTC pathogenesis.
The Worldwide Incidence of Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Assessment of global epidemiologic trends in incidence of biliary tract cancers (BTCs) showed higher BTC incidence in Asian versus Western countries as well as intraregional variations within countries, which is consistent with previous reports.
Capecitabine and Cisplatin as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Retrospective analysis data suggest that second-line chemotherapy of capecitabine and cisplatin combination therapy was associated with modest efficacy in patients with advanced biliary tract cancer.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Preliminary data suggest that dual blockade with ipilimumab and nivolumab might have antitumor activity in a subset of patients with microsatellite-stable biliary tract cancer.
Nivolumab with Chemotherapy or Ipilimumab: First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Phase 2 study results suggest that the addition of nivolumab and ipilimumab to chemotherapy as first-line therapy did not provide additional PFS benefit compared to standard-of-care chemotherapy in patients with advanced biliary tract cancer.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: